LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network

BACKGROUND: Prostate cancer threatens the health of men over sixty years old, and its incidence ranks first among all urinary tumors among men. Enzalutamide remains the first-line drug for castration-resistant prostate cancer, however, tumors inevitably become resistant to enzalutamide. Hence, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qingzhuo, Qiu, Hui, Piao, Chiyuan, Li, Zhengxiu, Cui, Xiaolu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436424/
https://www.ncbi.nlm.nih.gov/pubmed/37596700
http://dx.doi.org/10.1186/s13046-023-02774-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436424/
https://www.ncbi.nlm.nih.gov/pubmed/37596700
http://dx.doi.org/10.1186/s13046-023-02774-2

Ejemplares similares